Phase II study of sunitinib malate in head and neck squamous cell carcinoma
Latest Information Update: 14 Oct 2014
Price :
$35 *
At a glance
- Drugs Sunitinib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 06 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Apr 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 22 Jan 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.